Full-Time

Scientist – Protein Biochemistry

Protein Folding/Misfolding

Posted on 8/1/2024

BridgeBio

BridgeBio

501-1,000 employees

Develops medicines for genetic diseases

Compensation Overview

$130k - $165k/yr

+ Performance Bonus + Equity + Health Benefits

Mid, Senior

Palo Alto, CA, USA

Hybrid environment on the Stanford Life Sciences campus.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Requirements
  • D., MD, or Ph.D./MD degree and expertise in the field of **protein folding/misfolding** (e.g., biochemistry, biophysics, molecular biology, chemical biology, chemistry, structural biology). Prior industry experience or post-doctoral training is desirable but not required
  • Demonstrated record of achievement with at least one first-author publication in the field of protein folding/misfolding or chaperones is required
  • Experience and familiarity with techniques used for studying protein folding/misfolding, such as protein expression, purification, folding kinetics/pathway investigation, folding intermediate characterization, pulse proteolysis, protein thermal stability, urea denaturation, etc., is desirable
  • Experience with a wide range of biophysical (mass spectrometry (MS), surface plasmon resonance (SPR), microscale thermophoresis (MST), isothermal titration calorimetry (ITS), protein thermal shift (PTS), dynamic light scattering (DLS)) and plate-based biochemical (FRET, MSD, ELISA) techniques
  • Experience with multichannel pipettes and semi-automatic pipetting station is a plus
  • Experience with diseases related to protein folding/misfolding and pharmacological chaperones is a strong plus
  • Strong knowledge of chemistry concepts and structure biology, including an understanding of structure-activity relationships (SAR) and structure-based drug design.
Responsibilities
  • Use a variety of biochemical, biophysical, and pharmacological techniques to advance multiple small molecule drug candidates from discovery research to clinical development
  • Develop, optimize, troubleshoot, and execute novel biochemical and cellular assays to drive preclinical drug discovery
  • Interact with our medicinal chemists to support structural activity relationship learning
  • Drive basic research towards the clinic at hyperspeed
  • Independently design, execute, and analyze experiments within our top-notch laboratory
  • Communicate findings and implications to senior leadership

BridgeBio Pharma develops medicines specifically for genetic diseases, focusing on conditions with well-understood genetic causes. The company uses a decentralized subsidiary model, allowing each subsidiary to concentrate on specific diseases while sharing central resources. This structure enhances efficiency and enables the advancement of multiple drug programs at once. BridgeBio utilizes advancements in genome sequencing and molecular biology to identify and develop effective treatments. Their goal is to create significant therapeutic improvements by targeting diseases at their genetic source. With over 15 drug programs aimed at 20 different genetic diseases, BridgeBio aims to reduce the time it takes to bring new treatments to market. The company promotes a culture of independent thinking and transparency, which supports rapid, data-driven decision-making.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Palo Alto, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Recent approval of Beyonttra in Japan enhances BridgeBio's market presence.
  • Strategic partnerships expand BridgeBio's reach and resources in the biotech industry.
  • Advancements in AI and genetic data boost BridgeBio's R&D capabilities.

What critics are saying

  • Increased competition from Alnylam's Amvuttra may impact market share.
  • Financial risk from $500 million convertible senior notes if revenue projections fall short.
  • Reliance on Alexion for Beyonttra's commercial activity in Japan poses potential risks.

What makes BridgeBio unique

  • BridgeBio employs a decentralized subsidiary model for efficient drug development.
  • Focuses on genetic diseases with well-understood genetic causes for targeted therapies.
  • Leverages genome sequencing and molecular biology for innovative treatment solutions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Performance Bonus

Company Equity

Unlimited Paid Time Off

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

3%

2 year growth

0%
BioSpace
Mar 29th, 2025
Beyonttra(Tm) (Acoramidis), The First Near-Complete Ttr Stabilizer (>=90%), Approved In Japan To Treat Attr-Cm

In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-toleratedThe approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date. Key data from the ATTRibute-CM study include: In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalization (CVH)) durably separated relative to placebo A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30 A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30BridgeBio will receive a $30 million milestone payment from Alexion, AstraZeneca Rare Disease, with royalties in the low double digits on net sales of Beyonttra in JapanPALO ALTO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Japanese Ministry of Health, Labour and Welfare has approved acoramidis, under the brand name Beyonttra, for the treatment of adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Acoramidis is a selective small molecule, orally administered, near-complete (≥90%) transthyretin (TTR) stabilizer. Relative increases in serum TTR concentrations resulting from greater TTR stability have been associated with reduced risk of all-cause and cardiovascular mortality in the general population in recent literature.1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all commercial activity for Beyonttra in Japan.“There is significant need for new treatment options for ATTR-CM, a progressive, fatal disease, worldwide

BioSpace
Mar 25th, 2025
Bridgebio To Present Cardiovascular Outcomes Data In Patients With Variant And Wild-Type Transthyretin Amyloid Cardiomyopathy (Attr-Cm) From The Attribute-Cm Study At The Acc Annual Scientific Sessions

PALO ALTO, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that cardiovascular outcomes data in patients with variant and wild-type ATTR-CM from the ATTRibute-CM, its Phase 3 study of acoramidis in ATTR-CM, will be shared in a flatboard poster presentation at the American College of Cardiology (ACC) Annual Scientific Sessions & Expo, taking place in Chicago, Illinois on March 29-31, 2025. Additionally, BridgeBio was selected to share five poster presentations and two moderated posters on ATTR-CM.Flatboard Poster Presentations:Acoramidis Improves Serum TTR Levels in Patients with Wild-type or Variant Transthyretin Amyloid CardiomyopathyPresenter: Margot Davis, M.D. of Vancouver General Hospital, CADate: Monday, March 31 at 9:00 am CT/10:00 am ETAcoramidis Improves NYHA Class at Month 30 Versus Placebo in Patients with ATTR-CM: Results from the ATTRibute-CM StudyPresenter: Kevin Alexander, M.D. of Stanford University School of Medicine, USADate: Sunday, March 30 at 1:30 pm CT/2:30 pm ETIn Participants Treated with Acoramidis, Addition of Concomitant Tafamidis Did Not Further Increase Serum TTR LevelsPresenter: Mathew Maurer, M.D. of Columbia University Irving Medical Center, USADate: Monday, March 31 at 9:00 am CT/10:00 am ETRobustness of Primary Endpoint Efficacy Results with Acoramidis in ATTR-CM in the ATTRibute-CM Study: Pre-specified NT-proBNP Sensitivity AnalysesPresenter: Jan Griffin, M.D

Value the Markets
Mar 24th, 2025
Alnylam Pharmaceuticals Stock (ALNY): Innovative Treatment for ATTR Amyloidosis

Amvuttra will compete with Pfizer's Vyndaqel and BridgeBio's Attruby.

GlobeNewswire
Feb 26th, 2025
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt

Refinancing term debt facility lowers interest expense, eliminates near-term amortization payments, and significantly extends debt maturityOffering priced...

The Manila Times
Jan 8th, 2025
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference

PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) - BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.

INACTIVE